| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
21 |
27 |
56 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pyott David E I |
Director |
– • – |
2020-08-31 |
4 |
B |
$78.22 |
$1,001,715 |
D/D |
12,800 |
30,740 |
2.39 |
- |
|
| Grey Michael G |
Director |
– • – |
2020-08-03 |
4 |
AS |
$120.35 |
$300,875 |
D/D |
(2,500) |
42,840 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2020-08-03 |
4 |
OE |
$26.49 |
$66,225 |
D/D |
2,500 |
45,340 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2020-07-20 |
4 |
AS |
$130.00 |
$16,430,570 |
D/D |
(126,389) |
102,995 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2020-07-20 |
4 |
OE |
$63.10 |
$8,337,656 |
D/D |
126,389 |
229,384 |
|
- |
|
| Acosta Andrea |
GVP, Chief Accouning Officer |
• – – |
2020-07-17 |
4 |
D |
$128.21 |
$36,540 |
D/D |
(285) |
14,674 |
|
- |
|
| Acosta Andrea |
GVP, Chief Accounting OfficerO |
• – – |
2020-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,959 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2020-07-13 |
4 |
AS |
$130.00 |
$2,991,430 |
D/D |
(23,011) |
102,995 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2020-07-13 |
4 |
OE |
$63.10 |
$1,518,094 |
D/D |
23,011 |
126,006 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2020-07-09 |
4 |
GD |
$0.00 |
$0 |
I/I |
425 |
247,533 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2020-06-26 |
4 |
AS |
$123.61 |
$547,592 |
D/D |
(4,430) |
13,290 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2020-06-19 |
4 |
AS |
$124.00 |
$1,860,000 |
D/D |
(15,000) |
63,402 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2020-06-19 |
4 |
OE |
$63.10 |
$946,500 |
D/D |
15,000 |
78,402 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2020-06-05 |
4 |
AS |
$107.46 |
$476,048 |
D/D |
(4,430) |
18,850 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
51,968 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
42,840 |
|
- |
|
| Anderson Elizabeth M |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
8,790 |
|
- |
|
| Hombach Robert J. |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
16,210 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
84,340 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
17,720 |
|
- |
|
| Slamon Dennis |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
22,915 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
17,940 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,300 |
23,280 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2020-05-08 |
4 |
AS |
$91.72 |
$1,834,400 |
D/D |
(20,000) |
298,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2020-05-08 |
4 |
OE |
$21.51 |
$430,200 |
D/D |
20,000 |
318,552 |
|
- |
|
2582 Records found
|
|
Page 16 of 104 |
|
|
1.44 (1.6%) 
